Metastatic renal cell carcinoma (RCC) is advanced RCC with dissemination most commonly to lung, bone, liver, and brain. Clear cell biology predominates and is driven by VHL loss, HIF stabilization, intense angiogenesis, and context-dependent immune responsiveness that has made checkpoint blockade a core therapy in modern mRCC.
Ask a research question about Metastatic Renal Cell Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Metastatic Renal Cell Carcinoma
creation_date: '2026-03-28T21:30:00Z'
updated_date: '2026-05-10T11:58:43Z'
description: >-
Metastatic renal cell carcinoma (RCC) is advanced RCC with dissemination most
commonly to lung, bone, liver, and brain. Clear cell biology predominates and is
driven by VHL loss, HIF stabilization, intense angiogenesis, and context-dependent
immune responsiveness that has made checkpoint blockade a core therapy in modern
mRCC.
categories:
- Genitourinary Cancer
- Metastatic Cancer
- Solid Tumor
parents:
- renal cell carcinoma
disease_term:
preferred_term: metastatic renal cell carcinoma
term:
id: MONDO:0005086
label: renal cell carcinoma
mappings:
mondo_mappings:
- term:
id: MONDO:0005086
label: renal cell carcinoma
mapping_predicate: skos:closeMatch
mapping_source: MONDO
mapping_justification: Closest MONDO parent term available for metastatic renal cell carcinoma.
prevalence:
- population: Real-world metastatic RCC registry
percentage: 8.2
notes: Reported 5-year overall survival in a registry-era metastatic RCC cohort.
evidence:
- reference: PMID:28882737
reference_title: "Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: The 1-, 3-, and 5-year OS rate was 49.4%, 18.9%, and 8.2%, respectively.
explanation: This provides a long-term real-world survival estimate for mRCC.
pathophysiology:
- name: VHL Inactivation
description: >-
Biallelic VHL inactivation (somatic mutation, deletion, or promoter methylation)
is the
initiating lesion in most clear cell RCC, removing the E3 ligase adapter that
normally
targets HIF-α subunits for proteasomal degradation.
evidence:
- reference: PMID:37085424
reference_title: "Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: These include somatic gene mutations such as VHL, PBRM1, SETD2, and BAP1; copy number variations; transcriptomic multigene signatures; and specific immune cell populations.
explanation: This supports somatic VHL mutation as a defining genomic alteration in clear cell RCC.
biological_processes:
- preferred_term: proteasome-mediated VHL-dependent degradation of HIF-α
modifier: DECREASED
term:
id: GO:0043161
label: proteasome-mediated ubiquitin-dependent protein catabolic process
downstream:
- target: HIF Transcription Factor Stabilization
description: Loss of VHL-mediated ubiquitination prevents HIF-α degradation, allowing HIF accumulation.
- name: HIF Transcription Factor Stabilization
description: >-
Loss of functional pVHL prevents oxygen-dependent ubiquitination of HIF-α, producing
constitutively stabilized HIF transcription factors that activate hypoxia-response
programs even under normoxic conditions.
evidence:
- reference: PMID:36831657
reference_title: "Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance."
supports: SUPPORT
evidence_source: OTHER
snippet: Loss of pVHL function results in elevated levels of HIF-α due to increased stability, leading to RCC progression.
explanation: This directly supports HIF-α protein stabilization as the immediate consequence of VHL loss in ccRCC.
biological_processes:
- preferred_term: response to hypoxia
modifier: INCREASED
term:
id: GO:0001666
label: response to hypoxia
downstream:
- target: VEGF-Dependent Angiogenesis
description: Stabilized HIF drives transcription of VEGF and other angiogenic target genes.
- name: VEGF-Dependent Angiogenesis
description: >-
HIF activation drives VEGF-rich angiogenesis, producing the hypervascular phenotype
of
metastatic RCC and explaining the durable relevance of VEGF-targeted therapy.
evidence:
- reference: PMID:39670660
reference_title: "Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management."
supports: SUPPORT
evidence_source: OTHER
snippet: By inhibiting HIF-2α, belzutifan disrupts the transcription of genes involved in tumor growth and angiogenesis.
explanation: This supports the HIF-2α → angiogenesis transcriptional program as a druggable axis in clear cell RCC.
biological_processes:
- preferred_term: angiogenesis
modifier: INCREASED
term:
id: GO:0001525
label: angiogenesis
- name: Tumor Cell Invasion
description: >-
RCC cells acquire invasive capacity through EMT-like programs and stromal interactions,
enabling local tissue invasion and entry into the vasculature.
evidence:
- reference: PMID:36646679
reference_title: "Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: In addition, SERPINE2 could activate the epithelial-mesenchymal transition pathway.
explanation: EMT-pathway activation by a RCC-enriched factor supports EMT as the mechanistic basis for tumor cell acquisition of invasive capacity in mRCC.
biological_processes:
- preferred_term: epithelial to mesenchymal transition
modifier: INCREASED
term:
id: GO:0001837
label: epithelial to mesenchymal transition
downstream:
- target: Hematogenous Dissemination
description: Invading tumor cells enter the venous vasculature and seed distant sites, especially lung and bone.
- name: Hematogenous Dissemination
description: >-
After local invasion, RCC cells enter venous vasculature and spread hematogenously,
with a strong tropism for lung and bone.
evidence:
- reference: PMID:36646679
reference_title: "Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: SERPINE2 overexpression dramatically promoted RCC cell metastasis both in vitro and in vivo.
explanation: In vivo demonstration that a RCC-expressed factor drives metastatic dissemination of tumor cells directly supports hematogenous spread as a distinct downstream step from local invasion.
biological_processes:
- preferred_term: cell migration
modifier: INCREASED
term:
id: GO:0016477
label: cell migration
- name: Immune Microenvironment and Checkpoint Sensitivity
description: >-
Metastatic RCC often remains immunologically active enough to benefit from checkpoint
blockade, but clinical benefit is heterogeneous and influenced by pathologic response,
genomic context, and immune cell composition.
evidence:
- reference: PMID:41309336
reference_title: "Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Patients with an MPR at nephrectomy had longer PFS and OS.
explanation: This supports a clinically meaningful association between immunotherapy-induced pathologic response and survival in mRCC.
biological_processes:
- preferred_term: adaptive immune response
modifier: ABNORMAL
term:
id: GO:0002250
label: adaptive immune response
- name: Immune Evasion
description: >-
Despite immunogenic features, metastatic RCC can still evade host immunity through
suppressive myeloid populations, exhausted T-cell states, and nonuniform antigenic
pressure.
evidence:
- reference: PMID:36775874
reference_title: "EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: High lymphocyte infiltration and immunosuppression characterize the tumor microenvironment (TME) in renal cell carcinoma (RCC).
explanation: This supports that the mRCC tumor microenvironment is dominated by immunosuppressive features despite dense lymphocyte infiltration, consistent with active immune evasion.
biological_processes:
- preferred_term: negative regulation of immune response
modifier: INCREASED
term:
id: GO:0050777
label: negative regulation of immune response
phenotypes:
- category: Genitourinary
name: Hematuria
frequency: OCCASIONAL
description: Hematuria may persist from the primary renal lesion even after distant spread.
phenotype_term:
preferred_term: Hematuria
term:
id: HP:0000790
label: Hematuria
- category: Genitourinary
name: Flank pain
frequency: OCCASIONAL
description: Flank pain can reflect the primary renal mass or local extension.
phenotype_term:
preferred_term: Flank pain
term:
id: HP:0030157
label: Flank pain
- category: Musculoskeletal
name: Bone pain
frequency: FREQUENT
description: Bone metastases cause pain and skeletal-related events.
phenotype_term:
preferred_term: Bone pain
term:
id: HP:0002653
label: Bone pain
- category: Respiratory
name: Dyspnea
frequency: OCCASIONAL
description: Lung metastases may present with cough or dyspnea.
phenotype_term:
preferred_term: Dyspnea
term:
id: HP:0002094
label: Dyspnea
- category: Constitutional
name: Weight loss
frequency: FREQUENT
description: Weight loss is common in advanced systemic RCC.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
treatments:
- name: Immune Checkpoint Inhibitor Combination Therapy
description: >-
First-line systemic treatment for metastatic RCC commonly uses immune
checkpoint inhibitor combinations, either ICI-ICI or ICI plus a tyrosine
kinase inhibitor, selected by clinical risk and tolerability.
evidence:
- reference: DOI:10.1007/s00262-023-03621-1
reference_title: Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
supports: SUPPORT
evidence_source: OTHER
snippet: Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC).
explanation: This systematic review supports ICI-based combinations as a recommended first-line systemic treatment class for mRCC.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: nivolumab
term:
id: NCIT:C68814
label: Nivolumab
- preferred_term: pembrolizumab
term:
id: NCIT:C106432
label: Pembrolizumab
target_mechanisms:
- target: Immune Evasion
treatment_effect: INHIBITS
description: Checkpoint blockade targets suppressive immune signaling in the metastatic RCC tumor microenvironment.
- name: Belzutifan
description: >-
HIF-2 alpha inhibitor approved after prior PD-1/PD-L1 inhibitor and VEGF
tyrosine kinase inhibitor therapy for advanced renal cell carcinoma.
evidence:
- reference: DOI:10.1158/1078-0432.ccr-24-1199
reference_title: 'FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
explanation: FDA approval summary supports belzutifan as later-line targeted therapy for advanced RCC after checkpoint and VEGF-TKI exposure.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: belzutifan
term:
id: NCIT:C135627
label: Belzutifan
target_mechanisms:
- target: HIF Transcription Factor Stabilization
treatment_effect: INHIBITS
description: Belzutifan inhibits the HIF-2 alpha program downstream of VHL loss and HIF stabilization.
genetic:
- name: VHL
association: Somatic loss of function
notes: VHL loss is the initiating lesion in most clear cell RCC and underlies HIF addiction.
- name: PBRM1
association: Somatic loss of function
notes: PBRM1 mutation is common in clear cell RCC and may influence immunotherapy response.
- name: BAP1
association: Somatic loss of function
notes: BAP1 loss is associated with more aggressive metastatic behavior.
- name: SETD2
association: Somatic loss of function
notes: SETD2 mutation contributes to chromatin dysregulation and tumor evolution.
environmental:
- name: Smoking
notes: Smoking increases RCC risk and may contribute to aggressive disease biology.
- name: Obesity
notes: Obesity is a major RCC risk factor and influences inflammatory and metabolic signaling.
notes: >-
Lung and bone are common metastatic destinations in RCC, but the dominant mechanistic
theme is still VHL-HIF-driven angiogenic biology layered with heterogeneous immune
responsiveness.
references:
- reference: DOI:10.1007/s00262-023-03621-1
title: Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC).
supporting_text: Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC).
evidence:
- reference: DOI:10.1007/s00262-023-03621-1
reference_title: Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
supports: SUPPORT
evidence_source: OTHER
snippet: Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC).
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1007/s40620-024-01984-x
title: 'Air pollution and kidney cancer risk: a systematic review and meta-analysis'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Although several risk factors of kidney cancer have already been well-addressed, many remain underappreciated, such as chronic exposure to air pollution.
supporting_text: Although several risk factors of kidney cancer have already been well-addressed, many remain underappreciated, such as chronic exposure to air pollution.
evidence:
- reference: DOI:10.1007/s40620-024-01984-x
reference_title: 'Air pollution and kidney cancer risk: a systematic review and meta-analysis'
supports: SUPPORT
evidence_source: OTHER
snippet: Although several risk factors of kidney cancer have already been well-addressed, many remain underappreciated, such as chronic exposure to air pollution.
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1016/j.esmoop.2024.102994
title: 'Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: 'Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial'
supporting_text: 'Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial'
- reference: DOI:10.1038/s41591-024-03086-4
title: 'Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab.
supporting_text: Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab.
evidence:
- reference: DOI:10.1038/s41591-024-03086-4
reference_title: 'Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab.
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1038/s42003-024-05772-y
title: Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma.
supporting_text: Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma.
evidence:
- reference: DOI:10.1038/s42003-024-05772-y
reference_title: Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma.
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1056/nejmoa2212851
title: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
supporting_text: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
- reference: DOI:10.1093/oncolo/oyae180
title: Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years.
supporting_text: Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years.
evidence:
- reference: DOI:10.1093/oncolo/oyae180
reference_title: Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years.
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1158/1078-0432.ccr-24-1199
title: 'FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
supporting_text: FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
evidence:
- reference: DOI:10.1158/1078-0432.ccr-24-1199
reference_title: 'FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1186/s12916-024-03677-5
title: 'Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: 'Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort'
supporting_text: 'Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort'
- reference: DOI:10.1186/s12944-024-02138-5
title: 'Association between metabolic syndrome and kidney cancer risk: a prospective cohort study'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Kidney cancer has become known as a metabolic disease.
supporting_text: Kidney cancer has become known as a metabolic disease.
evidence:
- reference: DOI:10.1186/s12944-024-02138-5
reference_title: 'Association between metabolic syndrome and kidney cancer risk: a prospective cohort study'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Kidney cancer has become known as a metabolic disease.
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1200/jco.23.01569
title: 'Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Clinical trials frequently include multiple end points that mature at different times.
supporting_text: Clinical trials frequently include multiple end points that mature at different times.
evidence:
- reference: DOI:10.1200/jco.23.01569
reference_title: 'Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Clinical trials frequently include multiple end points that mature at different times.
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.3238/arztebl.m2024.0147
title: The treatment of metastatic renal cell carcinoma
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: The treatment of metastatic renal cell carcinoma
supporting_text: The treatment of metastatic renal cell carcinoma
- reference: DOI:10.3346/jkms.2024.39.e293
title: 'Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: 'Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database'
supporting_text: 'Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database'
- reference: DOI:10.3390/cancers16183234
title: 'Real-World Survival Outcomes of First-Line Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis from Two Centres in Saudi Arabia'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Metastatic renal cell carcinoma (mRCC) represents a challenging condition characterised by poor prognosis and limited response to chemoradiotherapy.
supporting_text: Metastatic renal cell carcinoma (mRCC) represents a challenging condition characterised by poor prognosis and limited response to chemoradiotherapy.
evidence:
- reference: DOI:10.3390/cancers16183234
reference_title: 'Real-World Survival Outcomes of First-Line Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis from Two Centres in Saudi Arabia'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Metastatic renal cell carcinoma (mRCC) represents a challenging condition characterised by poor prognosis and limited response to chemoradiotherapy.
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.3390/cells13010034
title: Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
supporting_text: The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
evidence:
- reference: DOI:10.3390/cells13010034
reference_title: Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
supports: SUPPORT
evidence_source: OTHER
snippet: The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.3390/cells13110961
title: 'First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm'
found_in:
- Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years.
supporting_text: The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years.
evidence:
- reference: DOI:10.3390/cells13110961
reference_title: 'First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm'
supports: SUPPORT
evidence_source: OTHER
snippet: The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years.
explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
Metastatic renal cell carcinoma (mRCC) refers to renal cell carcinoma that has spread beyond the kidney to distant organs (stage IV disease), typically requiring systemic therapy and multidisciplinary management; it remains “mainly treated palliatively” despite major therapeutic advances. (ivanyi2024thetreatmentof pages 1-2)
A clinically important modern framing is that mRCC treatment is dominated by immune checkpoint inhibitor (ICI) combinations (ICI–ICI or ICI–TKI), with additional local therapies (e.g., cytoreductive nephrectomy, metastasectomy, radiotherapy) considered case-by-case by a multidisciplinary tumor board. (ivanyi2024thetreatmentof pages 1-2, bloise2024firstlinetreatmentsand pages 2-4)
Primary histology context: RCC encompasses many subtypes; a 2024 review notes the WHO classification includes 39 RCC subtypes, and clear-cell RCC is the most common (~80%). (ivanyi2024thetreatmentof pages 1-2)
Abstract quote (definition/setting): “in 20–30% of cases, metastatic RCC (mRCC) is already present at the time of diagnosis. This disease in the metastatic stage is still mainly treated palliatively…” (ivanyi2024thetreatmentof pages 1-2)
Within retrieved evidence, explicit ICD-10/ICD-11, MeSH, Orphanet, or OMIM identifiers for the metastatic entity were not present. OpenTargets returned disease IDs for broader RCC entities (e.g., EFO_0000681 “renal cell carcinoma”, EFO_0005708 “renal cell adenocarcinoma”). (OpenTargets Search: renal cell carcinoma)
Commonly used equivalents in the retrieved literature include: - “advanced renal cell carcinoma” (aRCC) (powles2024nivolumabpluscabozantinib pages 1-2, yanagisawa2024updatedsystematicreview pages 4-4) - “advanced or metastatic renal cell carcinoma” (powles2024nivolumabpluscabozantinib pages 1-2) - “metastatic clear cell RCC (mccRCC)” (meng2023emergingimmunotherapyapproaches pages 5-6)
This report integrates: - Aggregated disease-level resources and reviews (systematic reviews/meta-analyses; guideline-focused reviews) (yanagisawa2024updatedsystematicreview pages 4-4, ivanyi2024thetreatmentof pages 1-2) - Randomized phase III trials and updates (CheckMate 9ER, CLEAR, COSMIC-313) (powles2024nivolumabpluscabozantinib pages 1-2, choueiri2023cabozantinibplusnivolumab pages 1-3, yanagisawa2024updatedsystematicreview pages 4-4) - Regulatory evidence (FDA approval summary for belzutifan) (fallah2024fdaapprovalsummary pages 1-3) - Real-world observational cohorts (metastatic site frequencies; real-world survival) (lee2024sitesofmetastasis pages 1-2, almansour2024realworldsurvivaloutcomes pages 1-2) - Single-cell translational studies (bone-metastatic microenvironment) (ma2024singlecellprofilingof pages 1-2)
Clear-cell RCC is strongly linked to dysregulation of hypoxia/angiogenesis programs (VHL–HIF signaling), which underlies the historic and current success of anti-angiogenic therapy and the newer HIF-2α inhibitor class. (OpenTargets Search: renal cell carcinoma, fallah2024fdaapprovalsummary pages 1-3)
OpenTargets disease–target associations highlight canonical RCC genes/targets (e.g., VHL, PBRM1, TP53, MET, MTOR) associated with renal cell carcinoma/adenocarcinoma. (OpenTargets Search: renal cell carcinoma)
Although these risk-factor studies are not restricted to metastatic disease, they inform upstream RCC incidence (and therefore mRCC burden).
Metabolic syndrome and components (UK Biobank, 2024): - Cohort: 355,678 participants, median follow-up 11 years, 1,203 kidney cancer cases. (wang2024associationbetweenmetabolic pages 1-2) - Risk vs metabolically healthy: - pre-MetS HR 1.36 (95% CI 1.06–1.74) (wang2024associationbetweenmetabolic pages 1-2) - MetS HR 1.70 (95% CI 1.30–2.23) (wang2024associationbetweenmetabolic pages 1-2) - Highest-risk component pattern reported: BP + HDL + WC HR 3.03 (95% CI 1.91–4.80). (wang2024associationbetweenmetabolic pages 5-6) - Joint effect with genetics: MetS + high polygenic risk score (PRS) HR 1.74 (95% CI 1.41–2.14) vs non‑MetS + low PRS, suggesting combined contribution of metabolic and inherited susceptibility. (wang2024associationbetweenmetabolic pages 1-2, wang2024associationbetweenmetabolic pages 5-6)
Dietary pattern (ultra-processed foods; PLCO cohort, 2024): - Cohort: ~101,688 participants; 410 RCC cases over 899,731 person-years (median follow-up 9.41 years) and 230 RCC deaths over 1,533,930 person-years (median follow-up 16.85 years). (li2024ultraprocessedfoodconsumption pages 1-2) - Highest vs lowest quartile of ultra-processed food consumption: - RCC incidence HR 1.42 (95% CI 1.06–1.91) (li2024ultraprocessedfoodconsumption pages 1-2) - RCC mortality HR 1.64 (95% CI 1.10–2.43) (li2024ultraprocessedfoodconsumption pages 1-2)
Air pollution (systematic review/meta-analysis, 2024; search through March 23, 2023): - Per 10 µg/m³ increase: - PM10 HR 1.29 (95% CI 1.10–1.51) (dahman2024airpollutionand pages 1-3) - NO2 HR 1.10 (95% CI 1.03–1.18) (dahman2024airpollutionand pages 1-3)
No specific protective factors with effect sizes were identified in the retrieved texts.
The UK Biobank analysis explicitly evaluated combined MetS and genetic risk. It reported that MetS plus high PRS conferred higher kidney cancer risk (HR 1.74, 95% CI 1.41–2.14), consistent with a joint contribution of metabolic exposures and polygenic risk to kidney cancer incidence. (wang2024associationbetweenmetabolic pages 1-2, wang2024associationbetweenmetabolic pages 5-6)
Note: The retrieved evidence set is treatment- and outcomes-focused and contains limited structured symptom/lab phenotype frequencies for mRCC. Below is a minimal phenotype set consistent with clinical context, plus ontology suggestions.
A 2024 review notes that only ~20% of RCC patients have “typical symptoms” at presentation (implying many are asymptomatic until advanced). (ivanyi2024thetreatmentof pages 1-2)
(These are ontology suggestions for knowledge-base structuring; frequencies were not extractable from retrieved sources.) - Hematuria — HP:0000790 - Flank pain — HP:0030765 - Abdominal mass — HP:0003278 - Weight loss — HP:0001824 - Fatigue — HP:0012378 - Anemia (common on therapy and in advanced disease) — HP:0001903 - Bone pain (bone metastasis) — HP:0002653 - Dyspnea (lung metastasis or treatment toxicity) — HP:0002094
Not directly quantified in retrieved texts; however, mRCC therapy is associated with high adverse-event burdens (e.g., grade ≥3 AEs) which plausibly affects QoL. (powles2024nivolumabpluscabozantinib pages 1-2, choueiri2023cabozantinibplusnivolumab pages 1-3, fallah2024fdaapprovalsummary pages 1-3)
OpenTargets RCC associations include genes central to RCC biology and hereditary syndromes, including VHL, PBRM1, FLCN, MET, MTOR, SETD2, KDM5C, TFE3, and BAP1 (depending on RCC subtype mapping in OpenTargets). (OpenTargets Search: renal cell carcinoma)
Ontology suggestions: - HGNC symbols: VHL, PBRM1, BAP1, SETD2, MTOR, MET
GO suggestions (biological process): - Angiogenesis — GO:0001525 - Response to hypoxia — GO:0001666 - T cell activation — GO:0042110
A 2024 single-cell study of bone metastatic RCC profiled 6 primary and 9 bone metastatic tumors from 14 ccRCC patients, reporting extensive immune dysfunction in bone metastases and a macrophage/MDSC axis. (ma2024singlecellprofilingof pages 1-2)
Key quantitative/biological statements from the excerpt include: - “More than one-third of metastatic RCC patients were accompanied by bone metastases.” (ma2024singlecellprofilingof pages 1-2) - “The progression-free survival of BMRCC remains low of 4.7 months versus 11.2 months for those without bone metastases.” (ma2024singlecellprofilingof pages 1-2) - Bone metastatic tumors show “multifaceted immune deficiency” with macrophages exhibiting “malignant and pro-angiogenic features,” dominance of “immune inhibitory T cells,” and MDSCs as macrophage progenitors. (ma2024singlecellprofilingof pages 1-2)
Cell Ontology (CL) suggestions (key cell types): - CD8-positive, alpha-beta T cell — CL:0000625 - Regulatory T cell — CL:0000815 - Macrophage — CL:0000235 - Myeloid-derived suppressor cell — CL:0000867 - Cancer-associated fibroblast — (no single CL term universally used; often modeled as fibroblast CL:0000057 with “activated” state)
mRCC outcomes reflect interplay between: - Angiogenesis dependence (TKI sensitivity) - Immune microenvironment state (ICI sensitivity) - Organ-specific niches (e.g., bone metastasis immune suppression) - Emerging targeting of HIF-2α as an upstream axis in clear-cell RCC biology. (powles2024nivolumabpluscabozantinib pages 1-2, yanagisawa2024updatedsystematicreview pages 4-4, ma2024singlecellprofilingof pages 1-2, fallah2024fdaapprovalsummary pages 1-3)
A large Korean multicenter database study (n=1,761) reported the most common metastatic sites at mRCC diagnosis: lung 70.9%, lymph nodes 37.9%, bone 30.7%, liver 12.7%, adrenal gland 9.8%, brain 8.2%. (lee2024sitesofmetastasis pages 1-2)
Median cancer-specific survival (CSS) varied by site, ranging from 13.9 months (liver) to 29.1 months (lung) among common sites (>5%); liver, bone, and pleural metastases were associated with the shortest median CSS (<19 months). (lee2024sitesofmetastasis pages 1-2)
UBERON suggestions: - Kidney — UBERON:0002113 - Lung — UBERON:0002048 - Bone — UBERON:0002481 - Liver — UBERON:0002107 - Brain — UBERON:0000955 - Adrenal gland — UBERON:0002369
A 2024 German review reports ~15,000 RCC diagnoses annually in Germany and notes that 20–30% present with metastatic disease at diagnosis. (ivanyi2024thetreatmentof pages 1-2)
A real-world Saudi cohort paper provides global framing figures (not limited to mRCC): “nearly 431,000 new RCC cases in 2022 with ~180,000 deaths,” and states ~35% of RCC patients present with unresectable/metastatic disease at diagnosis. (almansour2024realworldsurvivaloutcomes pages 1-2)
A 2024 review summarizes outcomes achievable with prognosis-based sequential systemic therapy: mean PFS 12–24 months and OS ≈50 months from first-line initiation. (ivanyi2024thetreatmentof pages 1-2)
IMDC risk group survivals reported in that review: low-risk 43.2 months, intermediate 22.5 months, high-risk 7.8 months. (ivanyi2024thetreatmentof pages 1-2)
The retrieved evidence emphasizes systemic-therapy management and does not provide a detailed diagnostic algorithm. In practice, mRCC diagnosis/staging relies on cross-sectional imaging (CT/MRI), histopathology, and risk stratification (IMDC). (ivanyi2024thetreatmentof pages 1-2)
In resected RCC (localized/high-risk), tumor-informed ctDNA is emerging as a prognostic marker for recurrence (relevant to identifying patients at risk of progression to metastatic disease).
A 2024 study using a personalized ctDNA assay (Signatera RUO) reported: - Pre-operative ctDNA detection in 18/36 (50%) patients. (correa2024associationofcirculating pages 1-2) - ctDNA positivity associated with inferior relapse-free survival (pre-op HR 2.70, P=0.046; post-op/any time HR 3.23, P=0.003). (correa2024associationofcirculating pages 1-2) - Relapse prediction performance among ctDNA-positive patients: sensitivity 84%, PPV 90%; post-surgical ctDNA positivity PPV 100%; NPV 64%; absence at both timepoints NPV 80%. (correa2024associationofcirculating pages 1-2)
Abstract quote (key point): “Detection of plasma ctDNA using a personalized assay is prognostic of recurrence in patients with resected RCC.” (correa2024associationofcirculating pages 1-2)
Contemporary 1L mRCC therapy is dominated by ICI-based combinations (IO/TKI or IO/IO). A 2024 review states: “mRCC can be treated with a combination of two immune checkpoint inhibitors (CPIs), a CPI and a tyrosine-kinase inhibitor (TKI) (evidence level IA), or a TKI as monotherapy…” (ivanyi2024thetreatmentof pages 1-2)
A 2024 network meta-analysis excerpt provides comparative phase III outcomes across major 1L regimens versus sunitinib (PFS, OS, ORR, CR rates), reinforcing that multiple regimens improve outcomes with different tradeoffs (e.g., higher PFS/ORR with IO/TKI vs durability with IO/IO). (yanagisawa2024updatedsystematicreview pages 4-4)
The following table summarizes major 2023–2024 trial evidence and regulatory developments.
| Trial (NCT) | Population/line | Regimens | Key efficacy outcomes | Key safety notes | Publication (journal, date, URL) | Evidence |
|---|---|---|---|---|---|---|
| CheckMate 9ER (NCT03141177) | Treatment-naïve advanced/metastatic clear-cell RCC; 1L; n=323 nivolumab+cabozantinib vs n=328 sunitinib | Nivolumab 240 mg IV q2w + cabozantinib 40 mg daily vs sunitinib 50 mg (4 weeks on, 6-week cycles) | Median PFS 16.6 vs 8.4 mo; HR 0.59 (95% CI 0.49–0.71). Median OS 49.5 vs 35.5 mo; HR 0.70 (95% CI 0.56–0.87). ORR 56% vs 28%; CR 13% vs 5%; median duration of response 22.1 vs 16.1 mo. | Treatment-related AEs any-grade/grade 3: 97%/67% vs 93%/55% with sunitinib. | ESMO Open, May 2024. https://doi.org/10.1016/j.esmoop.2024.102994 | (powles2024nivolumabpluscabozantinib pages 1-2) |
| CLEAR final OS analysis (NCT02811861) | Treatment-naïve advanced RCC; 1L; lenvatinib+pembrolizumab vs sunitinib | Lenvatinib 20 mg daily + pembrolizumab 200 mg IV q3w vs sunitinib | OS HR 0.79 (95% CI 0.63–0.99); median OS 53.7 vs 54.3 mo; 36-mo OS 66.4% vs 60.2%. Median PFS 23.9 vs 9.2 mo; HR 0.47 (95% CI 0.38–0.57). ORR 71.3% vs 36.7%. | Treatment-emergent AEs occurred in >90% of patients in both groups. | Journal of Clinical Oncology, Apr 2024. https://doi.org/10.1200/jco.23.01569 | (yanagisawa2024updatedsystematicreview pages 4-4) |
| COSMIC-313 (NCT03937219) | Previously untreated advanced clear-cell RCC with IMDC intermediate/poor risk; triplet intensification of IO/IO backbone; overall n=855 randomized | Cabozantinib 40 mg daily + nivolumab/ipilimumab vs placebo + nivolumab/ipilimumab | In first 550 randomized patients: 12-mo PFS probability 0.57 vs 0.49; HR for progression/death 0.73 (95% CI 0.57–0.94; P=0.01). ORR 43% vs 36%. OS follow-up ongoing. | Grade 3–4 AEs 79% vs 56%. | New England Journal of Medicine, May 2023. https://doi.org/10.1056/NEJMoa2212851 | (choueiri2023cabozantinibplusnivolumab pages 1-3) |
| LITESPARK-005 (NCT04195750) | Advanced RCC after prior PD-1/PD-L1 inhibitor and VEGF-TKI; randomized 1:1; n=746 | Belzutifan 120 mg daily vs everolimus 10 mg daily | PFS HR 0.75 (95% CI 0.63–0.90; 1-sided p=0.0008). Median PFS 5.6 vs 5.6 mo. OS HR 0.88 (95% CI 0.73–1.07), immature. Confirmed ORR 22% vs 3.6%. Led to FDA approval in Dec 2023 for post–PD-(L)1 and VEGF-TKI advanced RCC. | Toxicities differed by arm; discontinuations and interruptions due to treatment-emergent AEs were lower with belzutifan; PRO analyses suggested favorable tolerability. | Clinical Cancer Research (FDA Approval Summary), Sep 2024. https://doi.org/10.1158/1078-0432.CCR-24-1199 | (fallah2024fdaapprovalsummary pages 1-3) |
| CBM588 microbiome phase 1 (NCT05122546) | Treatment-naïve locally advanced or metastatic RCC; randomized phase 1; 30 participants; cabo+nivo ± live bacterial supplementation | Cabozantinib + nivolumab with or without CBM588 | Primary microbiome endpoint not met. ORR 74% (14/19) with CBM588 vs 20% (2/10) control; P=0.01. PFS at 6 mo 84% (16/19) vs 60% (6/10). | No significant difference in toxicity profile between study arms. | Nature Medicine, Jun 2024. https://doi.org/10.1038/s41591-024-03086-4 | (ma2024singlecellprofilingof pages 1-2) |
Table: This table summarizes key 2023-2024 systemic therapy evidence in metastatic or advanced renal cell carcinoma, including pivotal first-line and later-line studies. It highlights efficacy, safety, and publication details for quick comparison across major regimens.
FDA granted traditional approval (Dec 14, 2023) for belzutifan in advanced RCC after prior PD-(L)1 inhibitor and VEGF-TKI, based on LITESPARK-005 demonstrating PFS benefit vs everolimus (HR 0.75, 95% CI 0.63–0.90) and ORR 22% vs 3.6%. (fallah2024fdaapprovalsummary pages 1-3)
A 2024 retrospective real-world cohort of metastatic clear-cell RCC (n=84) reported median first-line PFS 9.7 months and median OS 42.0 months, with ORR 41% for ICI-based combinations (in that cohort) and identified liver metastasis and lower performance status as adverse prognostic factors. (almansour2024realworldsurvivaloutcomes pages 1-2)
A 2024 algorithm-focused review emphasizes multidisciplinary selection of cytoreductive nephrectomy and metastasectomy; it reports trial/observational signals that delayed nephrectomy strategies and complete metastasectomy can improve OS in selected patients (e.g., SURTIME mOS 32.5 vs 15 months; complete metastasectomy mOS 40.7 vs 14.8 months in the cited context). (bloise2024firstlinetreatmentsand pages 2-4)
Recent epidemiologic evidence supports risk reduction focusing on metabolic health, diet patterns, and environmental exposures: - Metabolic syndrome and combinations of metabolic abnormalities are associated with increased kidney cancer risk (e.g., MetS HR 1.70, BP+HDL+WC HR 3.03). (wang2024associationbetweenmetabolic pages 1-2, wang2024associationbetweenmetabolic pages 5-6) - Higher ultra-processed food intake is associated with higher RCC incidence and mortality (HR 1.42 and 1.64 for highest vs lowest quartile). (li2024ultraprocessedfoodconsumption pages 1-2) - Air pollution exposures PM10 and NO2 show positive associations with kidney cancer incidence in meta-analysis (PM10 HR 1.29; NO2 HR 1.10 per 10 µg/m³). (dahman2024airpollutionand pages 1-3)
No surveillance guideline text for hereditary RCC syndromes was retrieved in the current evidence set.
Not addressed in the retrieved evidence set.
Not addressed in the retrieved evidence set (no murine/xenograft/organoid model papers were retrieved).
References
(OpenTargets Search: renal cell carcinoma): Open Targets Query (renal cell carcinoma, 48 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(ivanyi2024thetreatmentof pages 1-2): Philipp Ivanyi, Tabea Fröhlich, Viktor Grünwald, Stefanie Zschäbitz, Jens Bedke, and Christian Doehn. The treatment of metastatic renal cell carcinoma. Deutsches Arzteblatt international, Aug 2024. URL: https://doi.org/10.3238/arztebl.m2024.0147, doi:10.3238/arztebl.m2024.0147. This article has 19 citations and is from a peer-reviewed journal.
(bloise2024firstlinetreatmentsand pages 2-4): Francesco Bloise, Fiorella Manfredi, Luca Zatteri, Giovanni Dima, Chiara Carli, Rosanna Di Vita, Maria Olivieri, Enrico Sammarco, Marco Ferrari, Alessia Salfi, Adele Bonato, Debora Serafin, Natalia Coccia, Laura Doni, Luca Galli, Michele Sisani, Giandomenico Roviello, Martina Catalano, and Federico Paolieri. First-line treatments and management of metastatic renal cell carcinoma patients: an italian interdisciplinary uro-oncologic group algorithm. Cells, 13:961, Jun 2024. URL: https://doi.org/10.3390/cells13110961, doi:10.3390/cells13110961. This article has 3 citations.
(powles2024nivolumabpluscabozantinib pages 1-2): T. Powles, M. Burotto, B. Escudier, A. Apolo, M. Bourlon, A. Shah, C. Suárez, C. Porta, C. Barrios, M. Richardet, H. Gurney, E. R. Kessler, Y. Tomita, J. Bedke, S. George, C. Scheffold, P. Wang, V. Fedorov, R. Motzer, T. Choueiri, and Prof. Thomas Powles. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase iii randomised checkmate 9er trial. ESMO Open, 9:102994, May 2024. URL: https://doi.org/10.1016/j.esmoop.2024.102994, doi:10.1016/j.esmoop.2024.102994. This article has 105 citations and is from a domain leading peer-reviewed journal.
(yanagisawa2024updatedsystematicreview pages 4-4): Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, Tatsushi Kawada, Satoshi Katayama, Kensuke Bekku, Ekaterina Laukhtina, Pawel Rajwa, Fahad Quhal, Benjamin Pradere, Wataru Fukuokaya, Kosuke Iwatani, Masaya Murakami, Karim Bensalah, Viktor Grünwald, Manuela Schmidinger, Shahrokh F. Shariat, and Takahiro Kimura. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. Cancer Immunology, Immunotherapy : CII, Jan 2024. URL: https://doi.org/10.1007/s00262-023-03621-1, doi:10.1007/s00262-023-03621-1. This article has 38 citations.
(meng2023emergingimmunotherapyapproaches pages 5-6): Lingbin Meng, Katharine A. Collier, Peng Wang, Zihai Li, Paul Monk, Amir Mortazavi, Zhiwei Hu, Daniel Spakowicz, Linghua Zheng, and Yuanquan Yang. Emerging immunotherapy approaches for advanced clear cell renal cell carcinoma. Cells, 13:34, Dec 2023. URL: https://doi.org/10.3390/cells13010034, doi:10.3390/cells13010034. This article has 72 citations.
(choueiri2023cabozantinibplusnivolumab pages 1-3): Toni K. Choueiri, Thomas Powles, Laurence Albiges, Mauricio Burotto, Cezary Szczylik, Bogdan Zurawski, Eduardo Yanez Ruiz, Marco Maruzzo, Alberto Suarez Zaizar, Luis E. Fein, Fabio A. Schutz, Daniel Y.C. Heng, Fong Wang, Fabio Mataveli, Yu-Lin Chang, Maximiliano van Kooten Losio, Cristina Suarez, and Robert J. Motzer. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. The New England journal of medicine, 388 19:1767-1778, May 2023. URL: https://doi.org/10.1056/nejmoa2212851, doi:10.1056/nejmoa2212851. This article has 188 citations and is from a highest quality peer-reviewed journal.
(fallah2024fdaapprovalsummary pages 1-3): Jaleh Fallah, Brian L. Heiss, Hee-Koung Joeng, Chana Weinstock, Xin Gao, William F. Pierce, Benjamin Chukwurah, Vishal Bhatnagar, Mallorie H. Fiero, Laleh Amiri-Kordestani, Richard Pazdur, Paul G. Kluetz, and Daniel L. Suzman. Fda approval summary: belzutifan for patients with advanced renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:5003-5008, Sep 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-1199, doi:10.1158/1078-0432.ccr-24-1199. This article has 23 citations.
(lee2024sitesofmetastasis pages 1-2): Chan Ho Lee, Minyong Kang, Cheol Kwak, Young Hwii Ko, Jung Kwon Kim, Jae Young Park, Seokhwan Bang, Seong Il Seo, Jungyo Suh, Wan Song, Cheryn Song, Hyung Ho Lee, Jinsoo Chung, Chang Wook Jeong, Jung Ki Jo, Seock Hwan Choi, Joongwon Choi, Changil Choi, Seol Ho Choo, Jang Hee Han, Sung-Hoo Hong, and Eu Chang Hwang. Sites of metastasis and survival in metastatic renal cell carcinoma: results from the korean renal cancer study group database. Journal of Korean Medical Science, Sep 2024. URL: https://doi.org/10.3346/jkms.2024.39.e293, doi:10.3346/jkms.2024.39.e293. This article has 19 citations and is from a peer-reviewed journal.
(almansour2024realworldsurvivaloutcomes pages 1-2): Mubarak M. Al-Mansour, Syed Sameer Aga, Hanin A. Alharbi, Maria N. Alsulami, Halah A. Fallatah, Tarfah B. Albedaiwi, Lujain K. Anbari, Taleen R. Surrati, Ashwag A. Algethami, Alaa Althubaiti, Turki M. Alfayea, and Ashwaq Alolayan. Real-world survival outcomes of first-line therapies in patients with metastatic clear cell renal cell carcinoma: a retrospective analysis from two centres in saudi arabia. Cancers, 16:3234, Sep 2024. URL: https://doi.org/10.3390/cancers16183234, doi:10.3390/cancers16183234. This article has 2 citations.
(ma2024singlecellprofilingof pages 1-2): Fen Ma, Shuoer Wang, Lun Xu, Wending Huang, Guohai Shi, Zhengwang Sun, Weiluo Cai, Zhiqiang Wu, Yiming Huang, Juan Meng, Yining Sun, Meng Fang, Mo Cheng, Yingzheng Ji, Tu Hu, Yunkui Zhang, Bingxin Gu, Jiwei Zhang, Shaoli Song, Yidi Sun, and Wangjun Yan. Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma. Communications Biology, Jan 2024. URL: https://doi.org/10.1038/s42003-024-05772-y, doi:10.1038/s42003-024-05772-y. This article has 12 citations and is from a peer-reviewed journal.
(wang2024associationbetweenmetabolic pages 1-2): Lin Wang, Han Du, Chao Sheng, Hongji Dai, and Kexin Chen. Association between metabolic syndrome and kidney cancer risk: a prospective cohort study. Lipids in Health and Disease, May 2024. URL: https://doi.org/10.1186/s12944-024-02138-5, doi:10.1186/s12944-024-02138-5. This article has 12 citations and is from a peer-reviewed journal.
(wang2024associationbetweenmetabolic pages 5-6): Lin Wang, Han Du, Chao Sheng, Hongji Dai, and Kexin Chen. Association between metabolic syndrome and kidney cancer risk: a prospective cohort study. Lipids in Health and Disease, May 2024. URL: https://doi.org/10.1186/s12944-024-02138-5, doi:10.1186/s12944-024-02138-5. This article has 12 citations and is from a peer-reviewed journal.
(li2024ultraprocessedfoodconsumption pages 1-2): Ya-Dong Li, Yong-Xin Fu, Le-Lan Gong, Ting Xie, Wei Tan, Hao Huang, Sheng-Jie Zeng, Chuan Liu, and Zheng-Ju Ren. Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort. BMC Medicine, Oct 2024. URL: https://doi.org/10.1186/s12916-024-03677-5, doi:10.1186/s12916-024-03677-5. This article has 9 citations and is from a domain leading peer-reviewed journal.
(dahman2024airpollutionand pages 1-3): Lina Dahman, Victoria Gauthier, Aurore Camier, Jean Joel Bigna, François Glowacki, Philippe Amouyel, Luc Dauchet, and Aghiles Hamroun. Air pollution and kidney cancer risk: a systematic review and meta-analysis. Journal of Nephrology, 37:1779-1790, Jun 2024. URL: https://doi.org/10.1007/s40620-024-01984-x, doi:10.1007/s40620-024-01984-x. This article has 16 citations and is from a peer-reviewed journal.
(correa2024associationofcirculating pages 1-2): Andres F Correa, Ekaterina Kalashnikova, Hsin-Ta Wu, Ryan M Winters, Mustafa Balcioglu, Sumedha Sudhaman, Denise C Connolly, Yulan Gong, Robert G Uzzo, Himanshu Sethi, Adam C ElNaggar, Alexey Aleshin, Minetta C Liu, and Philip H Abbosh. Association of circulating tumor dna with patient prognosis in surgically resected renal cell carcinoma. The Oncologist, 29:887-893, Jul 2024. URL: https://doi.org/10.1093/oncolo/oyae180, doi:10.1093/oncolo/oyae180. This article has 26 citations.